EQUITY RESEARCH MEMO

SciGenom

Generated 5/9/2026

Executive Summary

Conviction (model self-assessment)65/100

SciGenom is a leading genomics service provider founded in 2009, with state-of-the-art laboratories in Cochin, Chennai, Hyderabad, and a presence in Fremont, CA. The company offers end-to-end NGS, Sanger sequencing, bioinformatics, and real-time PCR services, leveraging Illumina and ABI platforms. Certified under NABL, ISO, and GLP, SciGenom serves research and diagnostics markets across India, Asia, and the USA. As a private entity, it is well-positioned to benefit from the growing demand for genomic services, particularly in emerging markets where cost-effective solutions are critical. The company’s DSIR-recognized R&D and proprietary SAIF database strengthen its competitive edge.

Upcoming Catalysts (preview)

  • Q3 2026Expansion of clinical diagnostic services in India70% success
  • Q4 2026Strategic partnership with a global pharma company for oncology genomics50% success
  • Q1 2027Launch of new liquid biopsy NGS panel60% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)